This cohort study used a Taiwan National Health Insurance data set to compare SGLT2i and dipeptidyl peptidase 4 inhibitors (DPP4i) use and the incidence of AKI and AKI-D in patients with T2D. The gene discussed is DPP4; the disease is type 2 diabetes mellitus.